BOSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BioAge Labs, Inc. (Nasdaq: BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bioa. What is this all about? Shares of BioAge Labs, Inc. were down 73% on December 9, after the company discontinued its STRIDES Phase 2 trial for azelaprag, ...

STOCKHOLM, Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's BrainTransporter™ technology. As part of the agreement, BioArctic will receive a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments. ...

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company devel ...

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). The investigation concerns whether BioAge and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for its lead product candidate, azelapr ...

SAN FRANCISCO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- On December 9, 2024, just months after conducting an initial public offering in September 2024, BioAge Labs, Inc. (NASDAQ: BIOA) made the startling announcement that it was discontinuing a Phase 2 study for its lead product, azelaprag, intended to treat metabolic diseases such as obesity. Hagens Berman has opened an investigation and urges investors in BioAge who purchased shares in the company’s IPO or on the open market and suffered substantial losses to su ...

NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Why is BioAge being Investigated? BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therap ...

ATLANTA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) complied with federal securities laws. On December 6, 2024, BioAge announced the discontinuation of the Strides Phase 2 study of its investigational drug candidate azelaprag due to safety concerns “after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.”  Following this news, the price of the Company ...

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Goldman Sachs Second Annual “Year-Ahead” Catalyst Clinic on Thursday, December 19, 2024, 11–12 PM EST. To access the live webcast of the virtual presentation, register here. Replays of the webcast will be ...

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference (New York, December 3-5, 2024): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42279 BIOAGE LABS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4721157 ( State or other jurisdict ...